Compare SER & FJET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | FJET |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4M | 48.7M |
| IPO Year | 2024 | 2026 |
| Metric | SER | FJET |
|---|---|---|
| Price | $1.44 | $0.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | 71.2K | ★ 1.2M |
| Earning Date | 11-24-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $130,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 132.14 | N/A |
| 52 Week Low | $1.14 | $0.67 |
| 52 Week High | $4.26 | $28.56 |
| Indicator | SER | FJET |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 38.84 |
| Support Level | $1.38 | $0.67 |
| Resistance Level | $2.13 | $0.96 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 17.73 | 44.47 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Starfighters Space Inc is a commercial aerospace company based at NASA's Kennedy Space Center in Florida, with an additional base of operations at Midland International Air & Space Port in Texas, and has a fleet of seven F-104 Fighter jets that are capable of flying MACH 2+. Its activities include air launch operations, pilot and space flight training, support research, hypersonic testing, and other aerospace development programs. The company has one operating segment, which is principally the operations of F-104 Fighter jets and the development of infrastructure for orbital space launch.